PMID- 29312572
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220314
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 65
DP  - 2017 Dec 12
TI  - Comparison of ALK status between primary and corresponding lymph node metastatic 
      tumors in lung cancer patients.
PG  - 108840-108847
LID - 10.18632/oncotarget.22294 [doi]
AB  - BACKGROUND: The anaplastic lymphoma kinase (ALK) protein has recently become a 
      promising target in the treatment of non-small cell lung carcinomas(NSCLC) 
      patients with ALK translocation because of the high response rates obtained with 
      an ALK inhibitor. ALK translocations are present in approximately 3-5% of NSCLC 
      patients. According to the literature, little information about the relationship 
      of ALK status between the primary tumor and metastatic sites has been reported. 
      We intended to determine whether the ALK translocations of primary lung cancers 
      are consistent with those in corresponding metastatic lymph node tumors. 
      MATERIALS AND METHODS: We analyzed ALK translocations from paired primary and 
      metastatic lymph node tumors in 78 lung cancer patients who had not received TKI 
      before the tissues were sampled. RESULTS: Using fluorescence in situ 
      hybridization (FISH) and immunohistochemistry (IHC) methods, all 45 patients with 
      ALK translocation-positive primary lung tumors had translocations in the 
      metastases. For 33 patients who were ALK negative in the primary tumors, 1 (3%) 
      was ALK positive in their metastatic tumors. CONCLUSION: According to a paired 
      t-test, there is no significant difference between primary lung tumors and 
      metastatic sites. Analysis of ALK translocations in the primary lung tumor would 
      be suitable for planning the use of a TKI for advanced NSCLC, but it would be 
      better to detect metastasis specimens as ALK negative specimens if both primary 
      and metastatic specimens have developed.
FAU - Gao, Qiqi
AU  - Gao Q
AD  - Department of Pathology, The First Affiliated Hospital, Zhejiang University, 
      Hangzhou, China.
FAU - Ma, Honghai
AU  - Ma H
AD  - Department of Thoracic Surgery, The First Affiliated Hospital, Zhejiang 
      University, Hangzhou, China.
FAU - Wang, Bo
AU  - Wang B
AD  - Department of Pathology, The First Affiliated Hospital, Zhejiang University, 
      Hangzhou, China.
FAU - Yao, Yake
AU  - Yao Y
AD  - Department of Respiration, The First Affiliated Hospital, Zhejiang University, 
      Hangzhou, China.
FAU - Zhou, Jianya
AU  - Zhou J
AD  - Department of Respiration, The First Affiliated Hospital, Zhejiang University, 
      Hangzhou, China.
FAU - Zhou, Jianying
AU  - Zhou J
AD  - Department of Respiration, The First Affiliated Hospital, Zhejiang University, 
      Hangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20171106
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5752485
OTO - NOTNLM
OT  - ALK
OT  - FISH
OT  - IHC
OT  - metastasis
OT  - non-small-cell lung cancer
COIS- CONFLICTS OF INTEREST The authors declare no conflicts of interest.
EDAT- 2018/01/10 06:00
MHDA- 2018/01/10 06:01
PMCR- 2017/12/12
CRDT- 2018/01/10 06:00
PHST- 2017/02/06 00:00 [received]
PHST- 2017/07/30 00:00 [accepted]
PHST- 2018/01/10 06:00 [entrez]
PHST- 2018/01/10 06:00 [pubmed]
PHST- 2018/01/10 06:01 [medline]
PHST- 2017/12/12 00:00 [pmc-release]
AID - 22294 [pii]
AID - 10.18632/oncotarget.22294 [doi]
PST - epublish
SO  - Oncotarget. 2017 Nov 6;8(65):108840-108847. doi: 10.18632/oncotarget.22294. 
      eCollection 2017 Dec 12.